GlassScriptPhysician profile
Michael Noah Gurell
NPI 1194834366
$3,974.30
in general payments reported to CMS, 2019-2025
19 companies · $884 in 2025
The $884 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $427 · 2021: $341 · 2022: $690 · 2023: $473 · 2024: $494 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,829 · Education: $22.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,828.61 |
| Education | $22.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,397.94 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $682.12 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.87 | 2019-2024 | Ofev |
| Mylan Specialty L.P. | $251.98 | 2019-2024 | Yupelri |
| Amgen INC. | $230.61 | 2022-2025 | Tezspire |
| Insmed, INC. | $210.16 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $182.40 | 2020-2025 | Dupixent |
| Electromed, INC. | $157.93 | 2024-2025 | Smartvest |
| Genzyme Corporation | $144.39 | 2023-2025 | |
| Grifols USA, LLC | $114.66 | 2020-2023 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $78.11 | 2019-2020 | |
| Verona Pharma, INC. | $67.90 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $55.11 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Takeda Pharmaceuticals U.S.A., INC. | $35.29 | 2025 | Glassia |
| Pfizer INC. | $31.33 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $27.78 | 2024 | Spin Vision Video Processor |
| Circassia INC. | $17.36 | 2019 | |
| Merck Sharp & Dohme LLC | $16.08 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gurell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.